Abstract:Introduction: Protein kinase C (PKC) is a promising drug target for various therapeutic areas. Natural products derived from plants, animals, microorganisms, and marine organisms have been used by humans as medicine from prehistoric times. Recently, several compounds derived from plants have been found to modulate PKC activities through competitive binding with ATP binding site, and other allosteric regions of PKC. As a result fresh race has been started in academia and pharmaceutical companies to develop an effective naturally derived small-molecule inhibitor to target PKC activities. Herein, in this review, we have discussed several natural products and their derivatives, which are reported to have an impact on PKC signaling cascade. Methods: All information presented in this review article regarding the regulation of PKC by natural products has been acquired by a systematic search of various electronic databases, including ScienceDirect, Scopus, Google Scholar, Web of science, ResearchGate, and PubMed. The keywords PKC, natural products, curcumin, rottlerin, quercetin, ellagic acid, epigallocatechin-3 gallate, ingenol 3 angelate, resveratrol, protocatechuic acid, tannic acid, PKC modulators from marine organism, bryostatin, staurosporine, midostaurin, sangivamycin, and other relevant key words were explored. Results: The natural products and their derivatives including curcumin, rottlerin, quercetin, ellagic acid, epigallocatechin-3 gallate, ingenol 3 angelate, resveratrol, bryostatin, staurosporine, and midostaurin play a major role in the management of PKC activity during various disease progression. Conclusion: Based on the comprehensive literature survey, it could be concluded that various natural products can regulate PKC activity during disease progression. However, extensive research is needed to circumvent the challenge of isoform specific regulation of PKC by natural products.

Patent landscape highlighting therapeutic implications of peptides targeting myristoylated alanine-rich protein kinase-C substrate (MARCKS)

Role for the PIP2‐binding protein myristoylated alanine‐rich C‐kinase substrate in vascular tissue: A novel therapeutic target for cardiovascular disease

An updated patent review of AKT inhibitors (2020 - present)

An updated patent review of Akt inhibitors (2016-present)

Protein kinase C inhibitors: a patent review (2010 - present)

AKT kinases as therapeutic targets

Therapeutic peptides for coronary artery diseases: in silico methods and current perspectives

Therapeutic cysteine protease inhibitors: a patent review (2018–present)

Innovative Therapeutic Approaches Targeting K-Ras: Analysis of Macrocyclic Compounds, Peptidomimetics, and Pyridopyrimidine Inhibitors

An updated patent review of protein arginine N-methyltransferase inhibitors (2019-2022)

Microtubule-affinity regulating kinase 4: A potential drug target for cancer therapy

Therapeutic targeting of microtubule affinity‐regulating kinase 4 in cancer and neurodegenerative diseases

Novel Patented Src Kinase Inhibitor

The therapeutic applications of antimicrobial peptides (AMPs): a patent review

Recent progress of protein kinase inhibitors derived from marine peptides for developing anticancer agents

Myristoylated Alanine-Rich protein Kinase C Substrate (MARCKS) expression modulates the metastatic phenotype in human and murine colon carcinoma in vitro and in vivo

Putative role of natural products as Protein Kinase C modulator in different disease conditions

Molecular Pathways: Targeting P21-Activated Kinase 1 Signaling in Cancer--opportunities, Challenges, and Limitations.

Kinase inhibitors: 20 years of success and many new challenges and recent trends in their patents

Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives

Recent developments in receptor tyrosine kinase inhibitors: A promising mainstay in targeted cancer therapy